Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer!
Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...
Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.
LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various ...
News-Medical.Net on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...
Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients with central precocious puberty (CPP), potentially opening the door | ...
Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care. Following the 2025 European Society of Medical Oncology (ESMO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback